Valuation: Lundbeck

Market Cap 3.91TCr 602.97Cr 523.56Cr 488.15Cr 448.44Cr 848.12Cr 57TCr 857.43Cr 5.76TCr 2.25TCr 29TCr 2.26TCr 2.21TCr 95TCr P/E 2026 *
8.85x
P/E 2027 * 8.87x
Enterprise Value 4.32TCr 665.8Cr 578.12Cr 539.02Cr 495.17Cr 936.49Cr 63TCr 946.77Cr 6.35TCr 2.48TCr 32TCr 2.5TCr 2.45TCr 1,04900Cr EV / Sales 2026 *
1.67x
EV / Sales 2027 * 1.51x
Free-Float
30.75%
Yield 2026 *
3.71%
Yield 2027 * 3.77%
1 day-0.07%
1 week-2.20%
Current month-1.39%
1 month-3.40%
3 months+1.87%
6 months+4.41%
Current year-1.93%
1 week 35.15
Extreme 35.15
36.65
1 month 35.15
Extreme 35.15
37.45
Current year 31.4
Extreme 31.4
39.9
1 year 28.65
Extreme 28.65
39.9
3 years 23.3
Extreme 23.3
41.7
5 years 21.94
Extreme 21.935
41.7
10 years 21.94
Extreme 21.935
41.7
Manager TitleAgeSince
Chief Executive Officer 59 01/10/2023
Director of Finance/CFO 49 01/09/2022
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 25/03/2015
Director/Board Member 66 25/03/2015
Director/Board Member 60 20/03/2018
Change 5-day change 1-year change 3-year change Capi.($)
-0.07%-2.20% - - 602.97Cr
+2.43%-4.14%+20.05%+101.73% 9.72TCr
+1.37%+3.42%+49.74%+156.93% 5.47TCr
+0.34%0.00%+3.47%+277.22% 2.4TCr
-1.07%+1.09%-13.34%-16.77% 826.57Cr
-0.28%-1.45%-34.89%-30.97% 740.13Cr
-0.52%-2.49%-8.63%-17.22% 690.33Cr
+0.71%-3.57%-1.45%+23.60% 520.66Cr
-1.75%+0.80%-6.81%-5.60% 373.76Cr
-1.93%-11.44%+6.31%+14.54% 359.49Cr
Average -0.08%-1.94%+1.61%+55.94% 2.35TCr
Weighted average by Cap. +1.36%-2.96%+20.45%+117.51%

Financials

2026 *2027 *
Net sales 2.58TCr 397.94Cr 345.53Cr 322.17Cr 295.96Cr 559.73Cr 38TCr 565.87Cr 3.8TCr 1.48TCr 19TCr 1.49TCr 1.46TCr 63TCr 2.58TCr 398.28Cr 345.83Cr 322.44Cr 296.21Cr 560.2Cr 38TCr 566.35Cr 3.8TCr 1.49TCr 19TCr 1.5TCr 1.46TCr 63TCr
Net income 456.04Cr 70Cr 61Cr 57Cr 52Cr 99Cr 6.68TCr 100Cr 670.65Cr 262.17Cr 3.34TCr 263.86Cr 258.08Cr 11TCr 456.78Cr 70Cr 61Cr 57Cr 52Cr 99Cr 6.69TCr 100.08Cr 671.74Cr 262.6Cr 3.35TCr 264.29Cr 258.5Cr 11TCr
Net Debt 407.78Cr 63Cr 55Cr 51Cr 47Cr 88Cr 5.98TCr 89Cr 599.68Cr 234.43Cr 2.99TCr 235.94Cr 230.77Cr 9.9TCr -96.35L -14.84L -12.89L -12.02L -11.04L -20.88L -14Cr -21.11L -1.42Cr -55.39L -7.06Cr -55.75L -54.52L -23Cr
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change Volume
05/26/05 DKK 35.50 0.00% 1,16,182
04/26/04 DKK 35.50 +0.28% 88,284
03/26/03 DKK 35.40 -1.67% 1,55,231
31/26/31 DKK 36.00 -0.28% 60,768
30/26/30 DKK 36.10 -0.55% 29,056
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
40.48DKK
Average target price
47.88DKK
Spread / Average Target
+18.27%

Quarterly revenue - Rate of surprise